JP2023519254A5 - - Google Patents
Info
- Publication number
- JP2023519254A5 JP2023519254A5 JP2022557776A JP2022557776A JP2023519254A5 JP 2023519254 A5 JP2023519254 A5 JP 2023519254A5 JP 2022557776 A JP2022557776 A JP 2022557776A JP 2022557776 A JP2022557776 A JP 2022557776A JP 2023519254 A5 JP2023519254 A5 JP 2023519254A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- approximately
- seq
- amino acids
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993570P | 2020-03-23 | 2020-03-23 | |
| US62/993,570 | 2020-03-23 | ||
| US202063041992P | 2020-06-21 | 2020-06-21 | |
| US63/041,992 | 2020-06-21 | ||
| US202163157618P | 2021-03-05 | 2021-03-05 | |
| US63/157,618 | 2021-03-05 | ||
| PCT/US2021/023430 WO2021194942A1 (en) | 2020-03-23 | 2021-03-22 | Anti-ccr8 antibodies for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519254A JP2023519254A (ja) | 2023-05-10 |
| JP2023519254A5 true JP2023519254A5 (cg-RX-API-DMAC7.html) | 2024-06-26 |
| JP7855519B2 JP7855519B2 (ja) | 2026-05-08 |
Family
ID=75478295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557776A Active JP7855519B2 (ja) | 2020-03-23 | 2021-03-22 | がんを処置するための抗ccr8抗体 |
Country Status (15)
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| AU2021277712B2 (en) | 2020-10-16 | 2023-05-25 | LaNova Medicines Limited | Anti-CCR8 monoclonal antibodies and uses thereof |
| WO2022211046A1 (ja) | 2021-03-31 | 2022-10-06 | 塩野義製薬株式会社 | Ccr8を抗原として認識するキメラ抗原受容体 |
| AU2022285741A1 (en) | 2021-06-04 | 2023-12-14 | Amgen Inc. | Anti-ccr8 antibodies and uses thereof |
| KR20240025013A (ko) * | 2021-06-25 | 2024-02-26 | 난징 이뮤노파지 바이오테크 코., 엘티디. | 항-ccr8 항체 및 이의 용도 |
| TWI920354B (zh) | 2021-07-27 | 2026-04-01 | 美商艾伯維有限公司 | 抗ccr8抗體 |
| CA3239784A1 (en) * | 2021-12-02 | 2023-06-08 | Lishan Kang | Ccr8 antigen binding unit and uses thereof |
| CN119930823A (zh) * | 2021-12-23 | 2025-05-06 | 乐普创一生物科技(上海)有限公司 | 抗ccr8抗体及其应用 |
| EP4463484A4 (en) * | 2022-01-14 | 2026-02-25 | Qilu Puget Sound Biotherapeutics Corp | Anti-ccr8 antibodies |
| TW202400648A (zh) * | 2022-04-29 | 2024-01-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ccr8抗體及其用途 |
| CN119948055A (zh) | 2022-05-24 | 2025-05-06 | 百时美施贵宝公司 | 结合人ccr8的抗体 |
| EP4536278A4 (en) | 2022-06-07 | 2026-08-12 | Actinium Pharmaceuticals Inc | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| CN115058387B (zh) * | 2022-06-11 | 2023-12-01 | 重庆医科大学 | 一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法 |
| WO2024026400A2 (en) * | 2022-07-27 | 2024-02-01 | Varian Medical Systems, Inc. | Therapeutic combinations of titr effectors with radiation therapy |
| AU2023319869A1 (en) * | 2022-08-04 | 2025-02-20 | Beone Medicines I Gmbh | Anti-ccr8 antibodies and methods of use |
| CA3265264A1 (en) * | 2022-08-19 | 2024-02-22 | Fibrogen, Inc. | CCR8 ANTIBODIES AND THEIR USES |
| WO2024052517A2 (en) | 2022-09-09 | 2024-03-14 | Bayer Aktiengesellschaft | Medical use of ccr8 antibodies and dosing schedule |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062019A1 (en) | 2022-09-21 | 2024-03-28 | Synabs | Anti-ccr8 antibodies and uses thereof |
| US20260234276A1 (en) | 2022-09-21 | 2026-08-13 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024077239A1 (en) * | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
| AU2023370501A1 (en) * | 2022-10-28 | 2025-05-01 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-ccr8 antibodies and uses thereof |
| CN120239710A (zh) | 2022-11-22 | 2025-07-01 | 上海宏成药业有限公司 | 抗ccr8抗体及其用途 |
| CN118324910A (zh) * | 2023-01-10 | 2024-07-12 | 北京天诺健成医药科技有限公司 | Ccr8抗体的应用 |
| TW202436351A (zh) | 2023-02-06 | 2024-09-16 | 德商拜耳廠股份有限公司 | Ccr8抗體及dgk抑制劑之組合 |
| WO2024248037A1 (ja) | 2023-05-30 | 2024-12-05 | 塩野義製薬株式会社 | Ccr8を抗原として認識する二重特異性抗体 |
| AU2024305430A1 (en) * | 2023-06-12 | 2026-01-22 | Nanjing Probio Biotech Co., Ltd. | Antibody binding to human ccr8 and the use thereof |
| CN122341642A (zh) | 2023-09-21 | 2026-07-03 | 多曼治疗学公司 | 抗ccr8单克隆抗体及其治疗用途 |
| WO2025061993A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| CN122374018A (zh) | 2023-10-06 | 2026-07-10 | 美国安进公司 | 用于癌症治疗的组合疗法 |
| IL327762A (en) * | 2023-10-17 | 2026-06-01 | Biontech Zhuhai Pharmaceuticals R&D Co Ltd | Bispecific antibody against ccr8 and ctla4 |
| CN117186202B (zh) * | 2023-11-08 | 2024-02-02 | 北京大学第三医院(北京大学第三临床医学院) | 一种新细胞因子csbf及其在干眼治疗中的应用 |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗fap-light融合蛋白及其用途 |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| CN119798438B (zh) * | 2023-12-29 | 2025-11-18 | 广东东阳光药业股份有限公司 | 一种抗ccr8单克隆抗体及其应用 |
| WO2025146065A1 (en) * | 2024-01-05 | 2025-07-10 | LaNova Medicines Limited | Clinical regimens of anti-ccr8 antibodies |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| WO2025191147A1 (en) | 2024-03-14 | 2025-09-18 | Synabs | Anti-ccr8 antibodies and uses thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260144884A1 (en) | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibody drug conjugates |
| US20260144885A1 (en) | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibodies and uses thereof |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007044756A2 (en) | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| AU2014201371A1 (en) * | 2007-10-31 | 2014-04-03 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| RU2682449C2 (ru) | 2012-09-19 | 2019-03-19 | Иннейт Фарма | Связывающие kir3dl2 агенты |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| MX378944B (es) | 2014-04-18 | 2025-03-10 | Univ New York State Res Found | Anticuerpos de antígeno anti-tf humanizado. |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| JP6983808B2 (ja) | 2016-01-08 | 2021-12-17 | メディトープ バイオサイセンシーズ インク.Meditope Biosciences, Inc. | 自己架橋性抗体 |
| JP7082051B2 (ja) | 2016-01-11 | 2022-06-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 抗原特異的cd8+t細胞の産生におけるインターロイキン-10及びその使用方法 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2018112032A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
| PT3431105T (pt) * | 2017-03-29 | 2020-03-11 | Shionogi & Co | Composição medicinal para tratamento de cancro |
| WO2019157098A1 (en) | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| CN110835371A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8单克隆抗体及其应用 |
| CN110835374A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8×ctla-4双特异性抗体及其应用 |
| BR112021011431A2 (pt) | 2018-12-27 | 2021-11-23 | Univ Osaka | Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit |
| TW202216771A (zh) * | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
-
2021
- 2021-03-22 AU AU2021244200A patent/AU2021244200A1/en active Pending
- 2021-03-22 CA CA3172697A patent/CA3172697A1/en active Pending
- 2021-03-22 EP EP21718409.2A patent/EP4126950A1/en active Pending
- 2021-03-22 TW TW110110284A patent/TW202202521A/zh unknown
- 2021-03-22 MX MX2022011701A patent/MX2022011701A/es unknown
- 2021-03-22 PE PE2022002058A patent/PE20230821A1/es unknown
- 2021-03-22 US US17/914,257 patent/US20230119066A1/en active Pending
- 2021-03-22 IL IL296673A patent/IL296673A/en unknown
- 2021-03-22 WO PCT/US2021/023430 patent/WO2021194942A1/en not_active Ceased
- 2021-03-22 JP JP2022557776A patent/JP7855519B2/ja active Active
- 2021-03-22 CN CN202180024063.9A patent/CN115768792A/zh active Pending
- 2021-03-22 KR KR1020227036358A patent/KR20220157446A/ko active Pending
- 2021-03-22 BR BR112022018636A patent/BR112022018636A2/pt active IP Right Grant
-
2022
- 2022-09-20 CL CL2022002555A patent/CL2022002555A1/es unknown
- 2022-09-21 CO CONC2022/0013599A patent/CO2022013599A2/es unknown
-
2025
- 2025-11-13 CL CL2025003540A patent/CL2025003540A1/es unknown
-
2026
- 2026-04-20 US US19/651,895 patent/US20260234278A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11718681B2 (en) | Anti-SIRP α antibodies | |
| AU2021202413B2 (en) | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors | |
| JP7855519B2 (ja) | がんを処置するための抗ccr8抗体 | |
| US20220098302A1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| Reichert et al. | The future of antibodies as cancer drugs | |
| TWI457124B (zh) | 包含專一性辨識cd38之抗體及長春新鹼(vincristine)之抗腫瘤組合 | |
| JP2021520201A5 (cg-RX-API-DMAC7.html) | ||
| JP2020501531A5 (cg-RX-API-DMAC7.html) | ||
| JP2018516969A5 (cg-RX-API-DMAC7.html) | ||
| CN118987201A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| JP2022512642A5 (cg-RX-API-DMAC7.html) | ||
| KR20200038530A (ko) | Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질 | |
| JP2021510736A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512642A (ja) | がんを治療するための抗MerTK抗体 | |
| JP2023543896A5 (cg-RX-API-DMAC7.html) | ||
| JP2024532886A5 (cg-RX-API-DMAC7.html) | ||
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| JP2024054123A (ja) | 癌の治療のための配合剤 | |
| JP2023525991A5 (cg-RX-API-DMAC7.html) | ||
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| EP3962525A1 (en) | Combination of her2 antibodies | |
| JP7036471B2 (ja) | デスレセプター4及びデスレセプター5に結合する非常に強力な抗体 | |
| JP2025508739A5 (cg-RX-API-DMAC7.html) | ||
| WO2023001118A1 (zh) | 抗ox40抗体在联合用药中的应用 | |
| Ozaki | 13 Biologic Therapies for Multiple Myeloma and Plasma Cell Disorders |